# Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

> **NCT03601975** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 336 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Gemcitabine/Cisplatin

## Key facts

- **NCT ID:** NCT03601975
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-27
- **Primary completion:** 2020-07-30
- **Final completion:** 2021-07-30
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03601975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03601975, "Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03601975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*